PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy

Company Update - PROCEPT BioRobotics announced that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for Aquablation therapy, a treatment for benign prostatic hyperplasia (BPH) [1] - The new Category I code will replace the existing Category III code starting January 1, 2026, with hospitals and physicians continuing to use the Category III code (0421T) until then [7] Product and Technology - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH, offering personalized treatment planning and precise tissue removal while preserving key anatomical functions [2] - The AquaBeam Robotic System, developed by PROCEPT BioRobotics, is an advanced, image-guided surgical robotic system designed for minimally invasive urologic surgery, specifically targeting BPH [4] Market and Clinical Evidence - BPH affects approximately 40 million men in the United States, making it the most common prostate disease [4] - PROCEPT BioRobotics has developed a significant body of clinical evidence, including nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy [4] Leadership and Industry Support - Reza Zadno, CEO of PROCEPT BioRobotics, expressed appreciation for the support and guidance provided by the American Urological Association during the CPT code approval process [2]